Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lei Fan

Showing results (1021-1030 of 1,041) with videos related to

Pageof 105
Sort By:
Ebiomedicine|April 11, 2025
Molecular heterogeneity of CD30<sup>+</sup> peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre studyYu-Jia Huo, Shu Cheng, Hong-Mei Yi, et al.
Thrombosis and Haemostasis|October 31, 2020
A Novel ABC Score Predicts Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Who underwent Percutaneous Coronary InterventionYing-Ying Zheng, Ting-Ting Wu, Ying Gao, et al.
Blood Cancer Journal|December 18, 2024
Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed/refractory angioimmunoblastic T-cell lymphomaMengyan Zhu, Ning Li, Lei Fan, et al.
Bone Marrow Transplantation|December 2, 2024
Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter studyJie Sun, Yi-Cheng Zhang, Jia Wei, et al.
American Journal of Hematology|September 8, 2025
Endothelial Activation and Stress Index Serves as a Predictor for Survival in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Multicenter Cohort Study of Jiangsu Cooperative Lymphoma GroupYanping Liu, Yimin Ren, Ling Gao, et al.
The Lancet. Oncology|January 11, 2024
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trialLei Fan, Zhong-Hua Wang, Lin-Xiaoxi Ma, et al.
JAMA|December 13, 2024
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical TrialLi Chen, Hui Li, Hao Zhang, et al.
Journal of Hematology & Oncology|January 13, 2021
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)Yuankai Shi, Jianqiu Wu, Zhen Wang, et al.
Therapeutic Advances in Medical Oncology|July 6, 2026
Clinical significance of high-density lipoprotein cholesterol and its dynamic change in patients with lymphoma-associated hemophagocytic lymphohistiocytosisJing Zhang, Jie Zhang, Shanza Ahmed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II TrialLi Chen, Yi-Zhou Jiang, Song-Yang Wu, et al.
Pageof 105

Showing results (1021-1030 of 1,041) with videos related to

Sort By:
Pageof 105
Ebiomedicine|April 11, 2025
Molecular heterogeneity of CD30<sup>+</sup> peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre studyYu-Jia Huo, Shu Cheng, Hong-Mei Yi, et al.
Thrombosis and Haemostasis|October 31, 2020
A Novel ABC Score Predicts Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Who underwent Percutaneous Coronary InterventionYing-Ying Zheng, Ting-Ting Wu, Ying Gao, et al.
Blood Cancer Journal|December 18, 2024
Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed/refractory angioimmunoblastic T-cell lymphomaMengyan Zhu, Ning Li, Lei Fan, et al.
Bone Marrow Transplantation|December 2, 2024
Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter studyJie Sun, Yi-Cheng Zhang, Jia Wei, et al.
American Journal of Hematology|September 8, 2025
Endothelial Activation and Stress Index Serves as a Predictor for Survival in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Multicenter Cohort Study of Jiangsu Cooperative Lymphoma GroupYanping Liu, Yimin Ren, Ling Gao, et al.
The Lancet. Oncology|January 11, 2024
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trialLei Fan, Zhong-Hua Wang, Lin-Xiaoxi Ma, et al.
JAMA|December 13, 2024
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical TrialLi Chen, Hui Li, Hao Zhang, et al.
Journal of Hematology & Oncology|January 13, 2021
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)Yuankai Shi, Jianqiu Wu, Zhen Wang, et al.
Therapeutic Advances in Medical Oncology|July 6, 2026
Clinical significance of high-density lipoprotein cholesterol and its dynamic change in patients with lymphoma-associated hemophagocytic lymphohistiocytosisJing Zhang, Jie Zhang, Shanza Ahmed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II TrialLi Chen, Yi-Zhou Jiang, Song-Yang Wu, et al.
Pageof 105